2010/06/23

Vagos

Method of production - an aerosol dose of 20 mg / dose

Pharmacotherapeutic group - m-holinoblokator

Pharmacological action
bronchodilatory
m-anticholinergic

Ingredients - ipratropium bromide 20 mcg - 1 dose

Statement
Vasomotor and allergic rhinitis
Respiratory
Asthma
Asthma unspecified
Asthma with a predominance of allergic component
Acute respiratory infection lower respiratory tract, unspecified
Acute bronchiolitis
Acute nasopharyngitis (common cold)
Non-allergic asthma
Mixed asthma
Chronic obstructive pulmonary disease, unspecified
Chronic obstructive pulmonary disease with exacerbation, unspecified
Chronic obstructive pulmonary disease with acute respiratory infection lower respiratory
Chronic rhinitis, nasopharyngitis and pharyngitis
Emphysema
Other chronic obstructive pulmonary disease
Other specified chronic obstructive pulmonary disease

The composition of the components
ipratropium bromide

Pharmacodynamics

It is a competitive antagonist of the neurotransmitter acetylcholine. Blocks muscarinic receptors of smooth muscles of the tracheobronchial tree and suppresses reflex bronhokonstriktsiyu, reduces the secretion of glands of the nasal mucosa and bronchial glands. Effectively prevents the bronchoconstriction resulting from exposure to cigarette smoke, cold air, the actions of various bronhokonstriktornyh substances, and also eliminates bronchospasm associated with the influence of the vagus nerves. Inhalation use almost no resorptive action.

Application

Treatment and prevention of chronic obstructive respiratory diseases: chronic obstructive bronchitis (with or without emphysema), bronchial asthma mild to moderate severity, particularly with concomitant diseases of the cardiovascular system, bronchospasm during surgery. Functional Tests for reversibility bronchoobstruction for the preparation of the respiratory tract before the introduction of aerosol antibiotics, mucolytic means, and corticosteroids. etc. Chronic rhinitis with hypersecretion (intranasal use).

Dosage regimen

Metered spray: Adults and children over 3 years - for prevention of respiratory failure in chronic obstructive bronchitis and asthma - to 0.4-0.6 (2-3 doses) several times a day (an average of 3 times), for treatment - can be further inhalation of 2-3 dose aerosol. Solution for inhalation: Adults and children over 6 years - 3-5 times a day. When using an electric sprayer or a respirator - 4-8 drops in a spray device, using hand sprayer - 20-30 breaths undiluted solution. Powder for inhalation: Adults and children over 6 years - 3 times a day inhalation contents of 1 capsule (200mkg) 3 times a day. In chronic rhinitis with intranasal spray applied hypersecretion: 2-3 doses in each nostril 3 raz. / day.

Side effects

Dry mouth, increased viscosity of sputum. Eye contact - accommodation disturbances in patients with angle-closure glaucoma may increase intraocular pressure. When using the nasal spray - dryness and irritation of the nasal mucosa, allergic reactions.

Contraindications

Hypersensitivity, the first trimester of pregnancy.

Interaction

Bronchodilators potentiates the effect of beta-sympathomimetics and xanthine derivatives (theophylline).

Cautions

Metered-dose aerosol for intranasal use is not recommended to be used in children under 6 years old. Precautions to appoint inhalation to patients with angle-closure glaucoma, urinary tract obstruction due to hypertrophy of the prostate gland.